Biotechnology
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-08-29 08:00
2044
Innovent Announces 2024 Interim Results and Business Updates
Strong commercial performance and significant pipeline milestones support sustained growth and innovation SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and com...
2024-08-28 18:42
3148
Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market
Singapore-based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL® Success provides "template for the internationalization of future vaccine and biologics development fromSingapore" – Dr. Raman Rao, CEO, Hilleman Laboratories Hilleman Laboratories ...
2024-08-28 00:00
2221
Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million
YANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments. During the reporting period, the company's total revenue was RMB 363 million, up 39% year-over-year. In this, the revenue from product sales wasRMB 332 million,...
2024-08-27 22:55
2780
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approv...
2024-08-27 17:00
2502
Constellar and MY Exhibition Forge Strategic Partnership to Boost Agri-Food Technology and Aquaculture in Singapore and Taiwan region
SINGAPORE, Aug. 27, 2024 /PRNewswire/ -- Constellar and MY Exhibition Co., Ltd are pleased to announce a strategic partnership to boost the agri-food tech and aquaculture sectors inSingapore and Taiwan region. This collaboration will contribute to the broader goal of leveraging technology to adva...
2024-08-27 14:00
15391
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value, and Proven Ability to Expedite Quality Clinical Programs
Avance Clinical streamlines its biotech clients' clinical trial operations, workflows, and data management, optimizing study efficiencies,minimizing costs, and accelerating trial timelines. SAN ANTONIO, Aug. 27, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the biotech contract researc...
2024-08-27 11:30
1333
ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment
BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr.Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Activ...
2024-08-27 09:00
1861
CStone Reports 2024 Interim Results and Recent Corporate Updates
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve atRMB 814 million as of June 30, 2024. * NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of aChina domestic anti-PD-L1 mAb. ...
2024-08-23 22:20
6958
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period endingJune 30, 2024 , along with several significant milestones achieved in recent months. Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, stated, "In the...
2024-08-23 12:32
3851
Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia's Chemicals and Pharmaceuticals
SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions)[1], the inauguralProcess Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from19 to 21 November 2024 at Singapore EXPO. The most comprehensive Pr...
2024-08-22 15:30
9390
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiat...
2024-08-22 08:00
2103
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-08-22 08:00
3183
Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption
New Veeva Pulse findings show congresses and early-career experts have the
strongest influence on patient outcomes
SINGAPORE, Aug. 21, 2024 /PRNewswire/ -- Veeva Systems
2024-08-21 09:00
2890
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal OptiTROP-Lung03 study has been accepted by the Center for Drug Evaluation (CDE)...
2024-08-20 16:32
1717
Allozymes and Adisseo Partner on Next-Gen Animal Feed Production Using Rapid Microfluidics Technology
SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Allozymes, a leading innovator in enzyme discovery and engineering, today announces a strategic partnership with Adisseo, one of the world's leading animal nutrition companies, to develop groundbreaking bioprocesses for animal feed ingredient production. T...
2024-08-19 15:57
1871
Ainex Unveils Advanced Endoscopy AI System at GIHEP & Singapore Hepatology Conference 2024
SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Ainex Corporation, a leading innovator in medical technology, has unveiled its advanced Endoscopy AI system, ENAD (Endoscopy as AI-powered Device), at the Combined GIHEP & Singapore Hepatology Conference 2024. This prestigious event, bringing together glob...
2024-08-19 08:01
2194
Alphamab Oncology Reports 2024 Interim Results and Business Highlights
SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months endedJune 30, 2024 and highlighted recent business progress. Financial Summary * For the six months ended June 30, 2024, we recorded total revenue of RMB ...
2024-08-16 11:18
3453
Cresilon Receives FDA Clearance for TRAUMAGEL
Hemostatic gel designed to control moderate to severe bleeding in seconds and save lives NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn -based biotechnology company focused on hemostatic medical device technologies, today announced it has received U.S. Food and Dru...
2024-08-15 20:45
2157
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biop...
2024-08-15 13:43
1867
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
6428
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4908
Premium Features, Budget Price: Don't Miss the Fossibot S3 Pro's Dual-Screen AMOLED Debut
2025-01-19 15:00
4400
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4275
TikTok "Refugees" Flock to U.S. Owned Rival, Triller
2025-01-19 03:53
4070